Saccharomyces boulardii in maintenance treatment of Crohn's disease
Saccharomyces boulardii in maintenance treatment of Crohn's disease
复制标题
DOI：
10.1023/a:1005588911207
复制
发表时间：
2000-07-01
影响因子：
3.1
通讯作者：
Testoni, PA
中科院分区：
文献类型：
--
作者：
Guslandi, M;Mezzi, G;Testoni, PA
已经评估了布氏酵母（一种对人类肠道有益的非致病性酵母）在克罗恩病维持治疗中的可能作用。32例克罗恩病临床缓解期（CDAI < 150）患者随机接受美沙拉嗪1g每日3次或美沙拉嗪1g每日2次加布拉酵母菌制剂1g每日治疗6个月。根据CDAI值评估，单独接受美沙拉嗪治疗的患者中有37.5%出现临床复发，接受美沙拉嗪加益生菌治疗的患者中有6.25%出现临床复发。我们的结果表明布拉酵母菌可能是维持治疗的有用工具克罗恩病。然而，考虑到产品的成本，需要进一步的对照研究来证实这些初步数据。
The possible role of Saccharomyces bouldardii, a nonpathogenic yeast with beneficial effects on the human intestine, in the maintenance treatment of Crohn's disease has been evaluated. Thirty-two patients with Crohn's disease in clinical remission (CDAI < 150) were randomly treated for six months with either mesalamine 1 g three times a day or mesalamine 1 g two times a day plus a preparation of Saccharomyces boulardii 1 g daily. Clinical relapses as assessed by CDAI values were observed in 37.5% of patients receiving mesalamine alone and in 6.25% of patients in the group treated with mesalamine plus the probiotic agent, Our results suggest that Saccharomyces boulardii may represent a useful tool in the maintenance treatment of Crohn's disease. However, in view of the product's cost, further controlled studies are needed to confirm these preliminary data.